Definition and epidemiology
Erectile dysfunction is defined as the consistent or recurrent inability to achieve or sustain a penile erection adequate for satisfactory sexual intercourse, present for a minimum of about 3 months (except in clearly identifiable acute-onset cases, e.g., post-surgical nerve injury).
- Prevalence increases markedly with age: roughly 1 in 10 men in their 40s, rising to over half of men by age 70, though mild degrees are even more common.
- ED shares risk factors with coronary artery disease, and symptomatic ED frequently precedes a cardiovascular event by 2-5 years because penile arteries are smaller caliber than coronary arteries and show atherosclerotic compromise earlier.
- Diabetes mellitus is one of the strongest independent risk factors, with ED prevalence several-fold higher than in age-matched nondiabetic men.
ICD-10 distinguishes F52.2 (sexual dysfunction not due to a substance or known physiological condition, i.e., psychogenic) from N48.4 (organic erectile dysfunction, including that due to vascular, neurogenic, hormonal, or drug-induced causes).
- New-onset ED is often an early marker of coronary artery disease — think 'penile artery before coronary artery.'
- Preserved nocturnal/morning erections suggest psychogenic ED; their loss suggests an organic cause.
- PDE5 inhibitors are absolutely contraindicated with nitrate use due to risk of severe hypotension.
- Diabetes mellitus is one of the strongest risk factors for organic ED via both vasculopathy and autonomic neuropathy.
- First-line workup includes fasting glucose/HbA1c, lipid panel, and morning testosterone.
- F52.2 codes psychogenic sexual dysfunction; N48.4 codes organic erectile dysfunction.
- Radical prostatectomy causes ED via bilateral cavernous nerve injury, impairing NO release.
- Erection physiology: parasympathetic NO release increases cGMP, relaxing corporal smooth muscle and trapping venous outflow.
Etiology and risk factors
ED is multifactorial; most cases in older men have mixed organic and psychogenic contributions.
Vascular (most common organic cause)
- Atherosclerosis / peripheral arterial disease
- Hypertension
- Hyperlipidemia
- Smoking
- Diabetes mellitus (vasculopathy and neuropathy)
Neurogenic
- Spinal cord injury
- Multiple sclerosis
- Pelvic/prostate surgery (radical prostatectomy) or pelvic radiation
- Peripheral neuropathy (diabetic autonomic neuropathy)
Hormonal
- Hypogonadism (low testosterone)
- Hyperprolactinemia (prolactinoma)
- Thyroid dysfunction
Drug-induced
- Antihypertensives (especially thiazide diuretics, older beta-blockers)
- SSRIs and other antidepressants
- Antipsychotics
- Finasteride, opioids, chronic alcohol use
Psychogenic
- Performance anxiety, depression, relationship conflict
- Classic clue: sudden onset, situational (occurs with one partner but not another), preserved nocturnal/morning erections
Anatomic/structural
- Peyronie disease
- Prior priapism with corporal fibrosis
Major modifiable risk factors overall: smoking, obesity, sedentary lifestyle, poorly controlled diabetes and hypertension, and metabolic syndrome.
Pathophysiology
Normal erection depends on parasympathetic (pelvic splanchnic, S2-S4) activation releasing nitric oxide (NO) from cavernosal nerve endings and endothelium. NO activates guanylate cyclase, increasing cGMP, which relaxes corporal smooth muscle and dilates the cavernosal arteries. Blood fills the sinusoids, compressing the subtunical venules against the tunica albuginea (veno-occlusive mechanism), trapping blood and producing rigidity. Detumescence occurs when phosphodiesterase type 5 (PDE5) breaks down cGMP.
- Vasculogenic ED: endothelial dysfunction and reduced NO bioavailability from atherosclerosis impair smooth muscle relaxation and arterial inflow; it is essentially a form of small-vessel vascular disease.
- Neurogenic ED: disruption of the autonomic pathways needed to initiate NO release.
- Hormonal ED: testosterone is permissive for libido and for normal PDE5 expression; deficiency reduces desire and may blunt the NO-cGMP response.
- Veno-occlusive dysfunction: structural changes in the tunica or smooth muscle (e.g., after priapism, Peyronie disease, aging) prevent adequate venous trapping even if arterial inflow is normal.
- Psychogenic ED: excess sympathetic tone (anxiety, stress) inhibits the parasympathetic erectile reflex centrally.
Clinical features
- Difficulty initiating an erection, maintaining it during intercourse, or both.
- Reduced spontaneous nocturnal/morning erections — suggests an organic cause when absent.
- Preserved nocturnal erections with situational failure — suggests psychogenic cause.
- Associated decreased libido raises suspicion for hypogonadism or depression.
- Gradual onset with risk factors (diabetes, smoking, hypertension) favors vascular etiology.
- Sudden onset after starting a new medication suggests drug-induced ED.
- Pain, curvature, or palpable plaque suggests Peyronie disease.
- Validated screening tool: the International Index of Erectile Function (IIEF-5) questionnaire quantifies severity and response to treatment.
Diagnosis
Diagnosis is largely clinical; the key goals are confirming ED, identifying reversible causes, and screening for underlying cardiovascular/metabolic disease.
History
- Onset (sudden vs gradual), situational variability, presence of nocturnal/morning erections
- Sexual history, relationship factors, psychological stressors
- Full medication and substance use review
- Cardiovascular, diabetes, and neurologic history
Physical examination
- Secondary sexual characteristics, testicular size and consistency
- Penile examination for plaques (Peyronie disease)
- Peripheral pulses, blood pressure
- Signs of hypogonadism (gynecomastia, decreased body hair)
Laboratory workup
- Fasting glucose/HbA1c and lipid profile (cardiovascular risk assessment — recommended in essentially all men with new ED)
- Morning total testosterone (repeat if low; add LH, prolactin if confirmed low)
- TSH if clinically indicated
Specialized testing (selected cases)
- Nocturnal penile tumescence testing (helps distinguish organic vs psychogenic)
- Intracavernosal injection test with duplex Doppler ultrasound (assesses arterial inflow)
- Penile angiography (rarely, before surgical revascularization in young trauma patients)
Because ED can be an early marker of coronary artery disease, new-onset ED in middle-aged or older men warrants cardiovascular risk assessment even if the patient is asymptomatic from a cardiac standpoint.
Differential diagnosis
| Condition | Distinguishing feature |
|---|---|
| Hypoactive sexual desire disorder | Loss of libido without necessarily impaired erectile mechanics |
| Premature ejaculation | Erection is normal; problem is timing of ejaculation |
| Peyronie disease | Painful curvature/plaque; erection may occur but is distorted |
| Hypogonadism | Low libido, fatigue, low testosterone; may coexist with ED |
| Depression/anxiety disorder | Situational ED, preserved nocturnal erections, mood symptoms |
| Priapism (prior episode) | History of prolonged painful erection causing corporal fibrosis |
| Drug-induced sexual dysfunction | Temporal relationship to new medication (SSRIs, antihypertensives) |
Management
Management follows a stepwise approach per AUA and European Association of Urology (EAU) guidelines, starting with lifestyle optimization and first-line pharmacotherapy.
Step 1: Address modifiable risk factors and reversible causes
- Smoking cessation, weight loss, exercise
- Optimize glycemic control, blood pressure, lipids
- Review and adjust offending medications
- Treat hypogonadism if testosterone is confirmed low (testosterone replacement) and treat hyperprolactinemia/thyroid disease if present
- Counseling/sex therapy when psychogenic factors predominate
Step 2: First-line pharmacotherapy — PDE5 inhibitors
- Sildenafil, tadalafil, vardenafil, avanafil
- Mechanism: inhibit PDE5, prolonging cGMP action and sustaining smooth muscle relaxation; require sexual stimulation and intact NO release to work
- Contraindicated with nitrates (risk of severe hypotension) — a classic exam point
- Use caution in men with recent unstable cardiac disease
Step 2 (alternative first-line in some guidelines): vacuum erection devices
- Mechanical option, useful when PDE5 inhibitors are contraindicated or ineffective
Step 3: Second-line therapy
- Intracavernosal injections (alprostatdil, often combined with papaverine/phentolamine)
- Intraurethral alprostadil
Step 4: Third-line therapy
- Penile prosthesis implantation (inflatable or malleable) for refractory cases
Other considerations
- Vascular surgery (penile revascularization) is reserved for young patients with focal arterial injury confirmed on imaging
- Psychosexual counseling is appropriate at any stage, especially with a psychogenic component or performance anxiety
- Partner involvement in counseling improves outcomes
Complications and prognosis
- ED itself is not life-threatening but significantly affects quality of life, self-esteem, and relationships, and is associated with depression and anxiety.
- It is an independent predictor of future cardiovascular events (myocardial infarction, stroke) and overall mortality, particularly when it precedes known cardiac disease.
- Response to PDE5 inhibitors is generally good in psychogenic and mild-to-moderate vascular/neurogenic disease; response is poorer after radical prostatectomy with bilateral nerve injury or in severe diabetic neuropathy/vasculopathy.
- Untreated hypogonadism-related ED may be associated with other sequelae of low testosterone (osteoporosis, reduced muscle mass, metabolic syndrome).
- With appropriate risk factor modification and treatment, most men achieve satisfactory improvement in erectile function and sexual satisfaction.
VINDICATE for ED causes: Vascular, Infective (rare), Neurogenic, Drugs, Idiopathic/psychogenic, Congenital/anatomic (Peyronie), Autoimmune/Atherosclerotic, Traumatic (pelvic), Endocrine (low testosterone).
Practice questions
1. A 58-year-old man with type 2 diabetes and hypertension reports gradual onset of erectile dysfunction over the past year. He still has morning erections occasionally but says they are less firm than before. He takes metformin and lisinopril. Physical exam is unremarkable. Which of the following is the most appropriate initial step in management?
2. A 24-year-old man presents with erectile dysfunction that occurs only with his new girlfriend; he reports normal firm erections during masturbation and has strong morning erections daily. He has no significant medical history and takes no medications. Which feature most strongly supports a psychogenic rather than organic cause?
3. A 67-year-old man with coronary artery disease on isosorbide mononitrate for angina asks his physician for a prescription for erectile dysfunction. Which of the following is the most appropriate response regarding PDE5 inhibitor therapy?
Frequently asked questions
What causes erectile dysfunction?
ED is usually caused by impaired blood flow to the penis from atherosclerosis, diabetes, or hypertension, though nerve damage, low testosterone, certain medications, and psychological factors like anxiety or depression are also common causes. Most cases in older men involve a combination of vascular disease and other contributing factors rather than a single cause.
What are the first symptoms of erectile dysfunction?
The first symptoms are typically difficulty achieving a firm enough erection for intercourse or trouble maintaining it, often with reduced spontaneous nocturnal or morning erections if the cause is organic. Some men also notice decreased sexual desire, which may point toward a hormonal or psychological contributor rather than purely a mechanical problem.
How is erectile dysfunction diagnosed?
Diagnosis starts with a detailed sexual and medical history plus physical exam, followed by basic labs including fasting glucose, lipid panel, and morning testosterone to screen for underlying diabetes, cardiovascular risk, and hypogonadism. Specialized tests like nocturnal penile tumescence monitoring or duplex ultrasound are reserved for ambiguous or treatment-resistant cases.
Is erectile dysfunction curable?
ED is often very treatable, though not always 'curable' in the sense of permanently reversing the underlying cause. Psychogenic and medication-induced ED can resolve completely with counseling or drug changes, while vascular or diabetic ED is usually managed long-term with PDE5 inhibitors and risk factor control rather than cured outright.
Erectile dysfunction vs low testosterone — what is the difference?
Low testosterone (hypogonadism) primarily reduces sexual desire (libido) and can contribute to ED, but many men with ED have entirely normal testosterone levels and a vascular or neurogenic cause instead. Testosterone testing helps distinguish the two, and ED from a purely hormonal cause typically improves with testosterone replacement, while vascular ED does not.
Key drugs
Related conditions and differentials
Sources and further reading
StatPearls (NCBI Bookshelf)MedlinePlusWHO ICD-10: F52.2
Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.